Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 8/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 8/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 8/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 8/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31312693 | 0.86 | PTPN5 (0.39) | MEN1LMNAKMT2APDK1PDK2 | |
| SCHEMBL24687401 | 0.85 | MEN1 (0.40) | MEN1LMNAKMT2APDK1PDK2 | |
| SCHEMBL16050285 | 0.83 | MEN1 (0.40) | MEN1LMNAKMT2APDK1PDK2 | |
| SCHEMBL23174526 | 0.81 | LMNA (0.43) | MEN1LMNAKMT2APDK1PDK2 | |
| SCHEMBL16122523 | 0.79 | PDK1 (0.40) | MEN1LMNAKMT2APDK1PDK2 | |
| SCHEMBL16050349 | 0.79 | MEN1 (0.40) | MEN1LMNAKMT2APDK1PDK2 | |
| SCHEMBL3932786 | 0.77 | HPGD (0.41) | MEN1LMNAKMT2AHTT | |
| SCHEMBL31515136 | 0.76 | PDK1 (0.40) | MEN1LMNAKMT2APDK1PDK2 | |
| SCHEMBL4568029 | 0.75 | PDK1 (0.50) | MEN1LMNAKMT2APDK1PDK2 | |
| SCHEMBL1197587 | 0.75 | PDK1 (0.50) | MEN1LMNAKMT2APDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MEN1 2993/4885LMNA 4472/4885KMT2A 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.